Adial Pharmaceuticals Stock Performance
| ADIL Stock | USD 0.51 0.06 13.33% |
On a scale of 0 to 100, Adial Pharmaceuticals holds a performance score of 2. The firm shows a Beta (market volatility) of -1.53, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Adial Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Adial Pharmaceuticals is expected to outperform it. Please check Adial Pharmaceuticals' jensen alpha, semi variance, day typical price, as well as the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether Adial Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Adial Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain forward indicators, Adial Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2.8 M |
Adial Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 68.00 in Adial Pharmaceuticals on April 22, 2025 and sell it today you would lose (17.00) from holding Adial Pharmaceuticals or give up 25.0% of portfolio value over 90 days. Adial Pharmaceuticals is currently generating 0.3801% in daily expected returns and assumes 14.4021% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Adial, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Adial Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adial Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Adial Pharmaceuticals, and traders can use it to determine the average amount a Adial Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0264
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ADIL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 14.4 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.38 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Adial Pharmaceuticals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Adial Pharmaceuticals by adding it to a well-diversified portfolio.
Adial Pharmaceuticals Fundamentals Growth
Adial Stock prices reflect investors' perceptions of the future prospects and financial health of Adial Pharmaceuticals, and Adial Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adial Stock performance.
| Return On Equity | -2.17 | ||||
| Return On Asset | -1.07 | ||||
| Current Valuation | 4.75 M | ||||
| Shares Outstanding | 15.78 M | ||||
| Price To Earning | (1.88) X | ||||
| Price To Book | 3.35 X | ||||
| EBITDA | (13.2 M) | ||||
| Cash And Equivalents | 9.16 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 975.86 K | ||||
| Debt To Equity | 0.03 % | ||||
| Book Value Per Share | 0.32 X | ||||
| Cash Flow From Operations | (6.92 M) | ||||
| Earnings Per Share | (0.87) X | ||||
| Total Asset | 5.04 M | ||||
| Retained Earnings | (82 M) | ||||
| Current Asset | 1.02 M | ||||
| Current Liabilities | 452.53 K | ||||
About Adial Pharmaceuticals Performance
By examining Adial Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Adial Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Adial Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Adial Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.Things to note about Adial Pharmaceuticals performance evaluation
Checking the ongoing alerts about Adial Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Adial Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Adial Pharmaceuticals had very high historical volatility over the last 90 days | |
| Adial Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Adial Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (13.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Adial Pharmaceuticals currently holds about 9.16 M in cash with (6.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35. |
- Analyzing Adial Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adial Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Adial Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Adial Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adial Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Adial Pharmaceuticals' stock. These opinions can provide insight into Adial Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.